FDA panel endorses Moderna’s COVID vaccine for children
FILE – Dr. Manjul Shukla transfers Pfizer COVID-19 vaccine into a syringe, Thursday, Dec. 2, 2021, at a mobile vaccination clinic in Worcester, Mass. Pfizer said Wednesday, Dec. 8, 2021, that a booster dose of its COVID-19 vaccine may protect against the new omicron variant even though the initial two doses appear significantly less effective. (AP Photo/Steven Senne, File)
ovp test
Male shot by female at Shreveport apartment
Class to create biodiverse backyard
Rules for outbursts at Caddo School Board Meeting
NEW YORK (AP) — An FDA advisory panel endorsed Moderna’s COVID-19 vaccine for teens and other school-age children on Tuesday.
Moderna’s COVID-19 vaccine has long been available for adults in the U.S. and elsewhere, and dozens of countries offer it to children, too. In the U.S., children ages 12 to 17 would get two full-strength doses; ages 6 to 11 would get half-size doses.
The FDA held up Moderna’s teen vaccine for months while it investigated a rare side effect, heart inflammation. That’s mostly a risk for teen boys and young men, and also can occur with the Pfizer vaccine. Moderna got extra scrutiny because its shots are a far higher dose..
In their review, FDA scientists said there were no confirmed cases of the heart inflammation in Moderna’s kid studies. But experts say the studies may have had too few participants for a rare side effect like that to appear.
“It’s just not enough people in the clinical trials to detect” the problem if it’s occurring, said Dr. Jesse Goodman of Georgetown University, a former FDA vaccine chief, in a call with reporters earlier this week.
As for other side effects, FDA officials said nothing alarming was reported — mainly sore arms, headache and fatigue.
The FDA analysis concluded that two doses of Moderna are effective in preventing symptomatic COVID-19 illness in teens and younger kids, with the levels of virus-fighting antibodies comparable to those developed in young adults.
Vaccine effectiveness was estimated at 93% for the 12-17 group, and 77% for the younger group, according to the FDA analysis. However, the research was done when earlier versions of the coronavirus were causing most U.S. infections, and it’s not clear how well the vaccinations will work against more recent variants. It’s also based on a limited number of COVID-19 cases, making the estimates a bit rough.
The FDA review said it was likely a booster shot would be needed, as is now recommended for children vaccinated with Pfizer’s shots, as well as for all adults.
How much demand there will be for Moderna’s shots isn’t clear. Teens became eligible a year ago for Pfizer’s vaccine, which uses the same technology, and only 60% have gotten two doses. Shots for younger kids started in November; about 29% have been fully vaccinated, according to the Centers for Disease Control and Prevention.
